Log fold change of IC50(or EC50for CCR3) of vMIP-II mutants versus WT for vMIP-II reversion mutants, tested at CCR3, CCR5, and CXCR4 in -arrestin recruitment assays (Figure S7I;STAR Methods). All datan= 3. WT vMIP-II and mutants tested as agonists (CCR3) or antagonists (CCR5: in competition with CCL5; CXCR4: in competition with CXCL12). SeeTable S2. See alsoFigure S7.
